209 related articles for article (PubMed ID: 37475207)
1. Retinal changes after fluocinolone acetonide implant (ILUVIEN®) for DME: SD-OCT imaging assessment using ESASO classification.
Leite J; Ferreira A; Castro C; Coelho J; Borges T; Correia N; Pessoa B
Eur J Ophthalmol; 2024 Jan; 34(1):233-244. PubMed ID: 37475207
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M
Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812
[TBL] [Abstract][Full Text] [Related]
3. Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema.
Holden SE; Habib M; Currie CJ
Curr Med Res Opin; 2020 Jun; 36(6):959-965. PubMed ID: 32267790
[No Abstract] [Full Text] [Related]
4. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.
Currie CJ; Holden SE; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):33-43. PubMed ID: 28881150
[TBL] [Abstract][Full Text] [Related]
5. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
Adams OE; Schechet SA; Hariprasad SM
Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
[TBL] [Abstract][Full Text] [Related]
6. Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema.
Pessoa B; Castro C; Ferreira A; Leite J; Heitor J; Menéres P; Figueira J; Meireles A; Beirão JM
Ophthalmic Res; 2022; 65(3):310-320. PubMed ID: 35086095
[TBL] [Abstract][Full Text] [Related]
7. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
Panos GD; Arruti N; Patra S
Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
[TBL] [Abstract][Full Text] [Related]
8. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
[TBL] [Abstract][Full Text] [Related]
9. Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results.
Chronopoulos A; Chronopoulos P; Ashurov A; Korb C; Pfeiffer N; Hattenbach LO
Eur J Ophthalmol; 2022 Jan; 32(1):443-449. PubMed ID: 33601897
[TBL] [Abstract][Full Text] [Related]
10. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Ranibizumab and Dexamethasone Implant Injections as Primary Treatment of Diabetic Macular Edema: The Month 24 Results from Simultaneously Double Protocol.
Kaya M; Atas F; Kocak N; Ozturk T; Ayhan Z; Kaynak S
Curr Eye Res; 2023 May; 48(5):498-505. PubMed ID: 36629472
[TBL] [Abstract][Full Text] [Related]
12. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
13. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
[TBL] [Abstract][Full Text] [Related]
14. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
[No Abstract] [Full Text] [Related]
15. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
16. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
17. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Soubrane G; Behar-Cohen F
J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
[TBL] [Abstract][Full Text] [Related]
18. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
Currie CJ; Holden SE; Berni E; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data.
Avogaro F; Florido A; Calandri A; Toja F; Vingolo EM
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):1759-1766. PubMed ID: 36930491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
